Edwards Lifesciences (NYSE:EW) Stock Gets Price Target Increase from Citigroup

Edwards Lifesciences (NYSE:EW) had its target price upped by equities research analysts at Citigroup from $110.00 to $117.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Citigroup‘s price target points to a potential upside of 16.18% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $115.00 price objective (up from $101.00) on shares of Edwards Lifesciences in a research note on Thursday. Deutsche Bank Aktiengesellschaft set a $104.00 target price on Edwards Lifesciences in a research report on Tuesday, October 27th. Argus increased their target price on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. The Goldman Sachs Group raised their target price on Edwards Lifesciences from $98.00 to $102.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Rothschild & Co Redburn boosted their price target on Edwards Lifesciences from $99.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $107.16.

Edwards Lifesciences Trading Up 1.3%

EW stock traded up $1.33 during midday trading on Thursday, reaching $100.70. 9,153,898 shares of the company’s stock traded hands, compared to its average volume of 4,523,223. The company has a market capitalization of $57.99 billion, a P/E ratio of 57.88, a PEG ratio of 2.49 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences has a fifty-two week low of $74.66 and a fifty-two week high of $104.17. The business has a 50-day moving average price of $88.48 and a two-hundred day moving average price of $85.61.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock worth $451,596 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of the business. Illinois Municipal Retirement Fund lifted its holdings in shares of Edwards Lifesciences by 15.7% during the third quarter. Illinois Municipal Retirement Fund now owns 46,772 shares of the medical research company’s stock worth $4,037,000 after buying an additional 6,359 shares in the last quarter. Bahl & Gaynor LLC boosted its position in shares of Edwards Lifesciences by 87.3% in the third quarter. Bahl & Gaynor LLC now owns 9,547 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 4,449 shares during the period. AMG National Trust Bank boosted its position in shares of Edwards Lifesciences by 6.1% in the third quarter. AMG National Trust Bank now owns 80,054 shares of the medical research company’s stock valued at $6,910,000 after acquiring an additional 4,582 shares during the period. Lido Advisors LLC grew its stake in shares of Edwards Lifesciences by 5.2% in the third quarter. Lido Advisors LLC now owns 34,192 shares of the medical research company’s stock valued at $2,951,000 after acquiring an additional 1,691 shares in the last quarter. Finally, Csenge Advisory Group grew its stake in shares of Edwards Lifesciences by 127.8% in the third quarter. Csenge Advisory Group now owns 14,437 shares of the medical research company’s stock valued at $1,246,000 after acquiring an additional 8,099 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, above the $0.74 consensus, and revenue of $1.72 billion, ahead of estimates and up 11.2% year over year. Strong structural-heart sales helped lift results. Edwards Lifesciences third-quarter results
• Positive Sentiment: The company raised its full-year adjusted EPS outlook to $2.97–$3.05. TMTT sales grew 45.6% and TAVR sales increased 8.8%, reinforcing growth across its heart-valve and repair businesses. Q3 earnings call highlights
• Positive Sentiment: PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes and hospitalizations, plus improved quality-of-life measures. The findings may support earlier use of the procedure. PROGRESS Trial data
• Positive Sentiment: Analysts raised targets following the results: Barclays to $120, JPMorgan to $120, RBC to $115, and Leerink Partners to $112. Baird upgraded EW to outperform, while Truist moved to strong buy, signaling improved sentiment about the outlook. Analyst reaction and market coverage
• Negative Sentiment: Edwards’ CEO said more competition is coming in TAVR. Greater competitive pressure could weigh on market share or pricing, tempering the otherwise favorable growth and trial news. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.